Abstract
The aim of the present study was to investigate the role of dopamine D3receptors in the rewarding effect and hyperlocomotion induced by a prototypical μ-opioid receptor agonist morphine using dopamine D3receptor knock-out mice. The μ-opioid receptor in the brain determined by the [tylosil-3,5-3H(N)]-[d-Ala2,N-MePhe4,Gly-ol5]enkephalin binding assay was not significantly changed by a deletion of the dopamine D3receptor gene. Furthermore, we found that no significant differences in G-protein activation by morphine in the limbic forebrain and lower midbrain were noted between the two genotypes. These results suggest that the function of the μ-opioid receptor itself was not affected by a deletion of the dopamine D3receptor gene. To ascertain the morphine-induced rewarding effect in both genotypes, the conditioned place preference paradigm was performed. Deletion of the dopamine D3receptor gene resulted in a remarkable enhancement of the morphine-induced rewarding effect. Furthermore, knock-out mice with deletions of the dopamine D3receptor revealed a dramatic potentiation of morphine-induced hyperlocomotion. Under these conditions, a loss of the dopamine D3receptor gene had no effect on the basal levels of dopamine and the increased dopamine turnover by morphine in the limbic forebrain. These findings provide further evidence that dopamine D3receptor contributes to the postsynaptically negative modulation of the mesolimbic dopaminergic pathway that is associated with the rewarding effect and hyperlocomotion through the stimulation of μ-opioid receptors induced by morphine in the mouse.
References
41
Referenced
52
10.1073/pnas.93.5.1945
10.1038/377424a0
10.1016/S0022-3565(25)10296-6
/ J Pharmacol Exp Ther / Neuroanatomical sites mediating the motivational effects of opioids as mapped by the conditioned place preference paradigm in rats. by Bals-Kubik (1993)10.1016/0006-8993(91)91456-B
10.1016/0003-2697(76)90527-3
10.1126/science.8099761
10.1146/annurev.pa.33.040193.001433
/ Annu Rev Pharmacol Toxicol / Molecular diversity of the dopamine receptors. by Civelli (1993)10.1016/0028-3908(93)90177-5
10.1016/S0006-8993(96)01438-2
/ Brain Res / Characterization of the effect of dopamine D3 receptor stimulation on locomotion and striatal dopamine levels. by De Boer (1997)10.1002/syn.890200209
10.1523/JNEUROSCI.20-23-08677.2000
10.1016/0304-3940(94)90342-5
/ Neurosci Lett / The role of dopamine D1-receptors in morphine-induced hyperlocomotion in mice. by Funada (1994)10.1016/0014-2999(96)00300-7
10.1146/annurev.ne.16.030193.001503
10.1007/BF02246265
10.1523/JNEUROSCI.18-06-02231.1998
10.1016/0165-6147(92)90060-J
10.1111/j.1460-9568.1993.tb00480.x
10.1016/S0031-6997(24)01327-9
/ Pharmacol Rev / The D3 dopamine receptor: neurobiology and potential clinical relevance. by Levant (1997)10.1016/S0006-8993(98)00146-2
10.1016/0028-3908(90)90004-B
/ Neuropharmacology / Chronic blockade of D2 but not D1 dopamine receptors facilitates behavioural responses to endogenous enkephalins, protected by kelatorphan, administered in the accumbens in rats. by Maldonado (1990)10.1038/41567
10.1016/0014-2999(93)90674-7
10.1016/0024-3205(93)90153-T
10.1016/S0163-7258(00)00099-1
10.1016/S0306-4522(01)00515-2
10.1016/S0304-3940(02)00235-5
/ Neurosci Lett / Intensification of the development of ethanol dependence in mice lacking dopamine D3 receptor. by Narita (2002)10.1016/0024-3205(83)90159-5
10.1016/0169-328X(95)00112-6
10.1016/S0092-8674(00)80365-7
10.1016/0006-8993(87)91571-X
10.1016/0014-2999(88)90803-5
10.1016/S0022-3565(25)38109-7
/ J Pharmacol Exp Ther / Examination of the neurochemical substrates mediating the motivational effects of opioid: role of the mesolimbic dopamine system and D-1 vs. D-2 dopamine receptors. by Shippenberg (1993)10.1038/347146a0
10.1007/BF00428196
/ Psychopharmacology / Chronic neuroleptic treatment and mesolimbic dopamine denervation induce behavioural supersensitivity to opiates. by Stinus (1985)10.1016/0006-3223(86)90006-5
10.1007/BF02247122
/ Psychopharmacology / Drug interactions in the reinforcing effects of over-the-counter cough syrups. by Suzuki (1990)10.1016/0304-3940(95)11334-S
/ Neurosci Lett / The D3-receptor agonist (+/−)-7-hydroxy-N,N-di-n-propyl-2-aminotetralin (7-OH-DPAT) attenuates morphine-induced hyperlocomotion in mice. by Suzuki (1995)10.1007/BF01244979
10.1146/annurev.ps.40.020189.001203
10.1016/S0896-6273(00)80965-4
Dates
Type | When |
---|---|
Created | 7 years, 4 months ago (April 13, 2018, 6:30 p.m.) |
Deposited | 1 month, 3 weeks ago (July 3, 2025, 1:33 p.m.) |
Indexed | 1 month, 3 weeks ago (July 4, 2025, 12:11 a.m.) |
Issued | 22 years, 6 months ago (Feb. 1, 2003) |
Published | 22 years, 6 months ago (Feb. 1, 2003) |
Published Online | 22 years, 6 months ago (Feb. 1, 2003) |
Published Print | 22 years, 6 months ago (Feb. 1, 2003) |
@article{Narita_2003, title={Molecular Evidence for the Functional Role of Dopamine D3Receptor in the Morphine-Induced Rewarding Effect and Hyperlocomotion}, volume={23}, ISSN={1529-2401}, url={http://dx.doi.org/10.1523/jneurosci.23-03-01006.2003}, DOI={10.1523/jneurosci.23-03-01006.2003}, number={3}, journal={The Journal of Neuroscience}, publisher={Society for Neuroscience}, author={Narita, Minoru and Mizuo, Keisuke and Mizoguchi, Hirokazu and Sakata, Mamoru and Narita, Michiko and Tseng, Leon F. and Suzuki, Tsutomu}, year={2003}, month=feb, pages={1006–1012} }